[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis. A 47-year-old man with renal cell carcinoma was admitted in our institution because of hypercalcemia with multiple metastasis in bone, lung and lymph nodes. After embolization of the right renal artery, the patient was treated with pamidronate and interferon-alpha. Intravenous pamidronate significantly reduced bone pain and normalized the serum calcium level. The pulmonary metastasis responded to interferon therapy after 2 months of therapy. Radical nephrectomy was then carried out. Paraaortic lymph nodes were found to be necrosed completely. Ossification of osteolytic lesions was observed after two months of therapy and metastatic lesions in the lung showed complete remission (CR) after six months of therapy.
Kise
H
H
Department of Urology, Mie University School of Medicine.
Kobayashi
K
K
Arima
K
K
Yanagawa
M
M
Tochigi
H
H
Kawamura
J
J
Hioki
T
T
Sugiura
Y
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000008:administration & dosage*; D006801:Humans; D006934:Hypercalcemia / Q000150:complications*; D016898:Interferon-alpha / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D000077268:Pamidronate
D000970:Antineoplastic Agents; D004164:Diphosphonates; D016898:Interferon-alpha; D000077268:Pamidronate